ibm watson truven health marketscan commercial claims and encounters (ccae) database (Truven Health)
90
Structured Review
Truven Health
ibm watson truven health marketscan commercial claims and encounters (ccae) database
Ibm Watson Truven Health Marketscan Commercial Claims And Encounters (Ccae) Database, supplied by Truven Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/marketscan+ccae/truven+ibm+watson+health+marketscan+medicaid+database/pm40586645-62-9-3
Average 90 stars, based on 1 article reviews
Ibm Watson Truven Health Marketscan Commercial Claims And Encounters (Ccae) Database, supplied by Truven Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/marketscan+ccae/truven+ibm+watson+health+marketscan+medicaid+database/pm40586645-62-9-3
Average 90 stars, based on 1 article reviews
ibm watson truven health marketscan commercial claims and encounters (ccae) database - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Comparison:Article Title: Association of Hemoglobin A 1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin Article Snippet: Study Site N Hazard Ratio 95% CI Lower bound 95% CI Upper bound P-Value Calibrated PValue Truven Marketscan CCAE 11558 1.08 0.99 1.17 0.09 0.56 Columbia University 281 1.25 0.79 2.00 0.35 0.60 IQVIA Disease Analyser France 1056 0.75 0.40 1.38 0.36 0.13 Truven Marketscan MDCR 1554 1.04 0.89 1.21 0.66 0.73 Mt Sinai 1013 0.76 0.55 1.03 0.07 0.01 Optum Clinformatics Data Mart 29060 1.12 1.07 1.17 0.00 0.78 Ajou University 594 2.67 1.10 7.43 0.04 0.00 Stanford University 147 2.25 1.17 4.61 0.02 0.00 Comparison: Sulfonylureas vs DPP4 inhibitors - Outcome: Eye Disorders Study Site N Hazard Ratio 95% CI Lower bound 95% CI Upper bound P-Value Calibrated PValue Truven Marketscan CCAE 10925 1.11 1.03 1.20 0.01 0.26 Columbia University 269 1.31 0.64 2.75 0.47 0.67 IQVIA Disease Analyser France 1083 3.00 0.69 20.47 0.20 0.30 Truven Marketscan MDCR 1227 1.10 0.94 1.29 0.24 0.72 Mt Sinai 1006 1.18 0.77 1.81 0.45 0.78 Optum Clinformatics Data Mart 26460 1.16 1.11 1.21 0.00 0.46 Ajou University 599 3.50 1.26 12.35 0.03 0.00 Stanford University 135 1.75 0.75 4.38 0.21 0.09 Comparison: Sulfonylureas vs Thiazolidinediones - Outcome: HbA1c Study Site N Hazard Ratio 95% CI Lower bound 95% CI Upper bound P-Value Calibrated PValue © 2018 Vashisht R et al. JAMA Network Open. .. Significance Assay:Article Title: Association of Hemoglobin A 1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin Article Snippet: Study Site N Hazard Ratio 95% CI Lower bound 95% CI Upper bound P-Value Calibrated PValue Truven Marketscan CCAE 11558 1.08 0.99 1.17 0.09 0.56 Columbia University 281 1.25 0.79 2.00 0.35 0.60 IQVIA Disease Analyser France 1056 0.75 0.40 1.38 0.36 0.13 Truven Marketscan MDCR 1554 1.04 0.89 1.21 0.66 0.73 Mt Sinai 1013 0.76 0.55 1.03 0.07 0.01 Optum Clinformatics Data Mart 29060 1.12 1.07 1.17 0.00 0.78 Ajou University 594 2.67 1.10 7.43 0.04 0.00 Stanford University 147 2.25 1.17 4.61 0.02 0.00 Comparison: Sulfonylureas vs DPP4 inhibitors - Outcome: Eye Disorders Study Site N Hazard Ratio 95% CI Lower bound 95% CI Upper bound P-Value Calibrated PValue Truven Marketscan CCAE 10925 1.11 1.03 1.20 0.01 0.26 Columbia University 269 1.31 0.64 2.75 0.47 0.67 IQVIA Disease Analyser France 1083 3.00 0.69 20.47 0.20 0.30 Truven Marketscan MDCR 1227 1.10 0.94 1.29 0.24 0.72 Mt Sinai 1006 1.18 0.77 1.81 0.45 0.78 Optum Clinformatics Data Mart 26460 1.16 1.11 1.21 0.00 0.46 Ajou University 599 3.50 1.26 12.35 0.03 0.00 Stanford University 135 1.75 0.75 4.38 0.21 0.09 Comparison: Sulfonylureas vs Thiazolidinediones - Outcome: HbA1c Study Site N Hazard Ratio 95% CI Lower bound 95% CI Upper bound P-Value Calibrated PValue © 2018 Vashisht R et al. JAMA Network Open. .. |